Travere Therapeutics (TVTX) Operating Leases: 2020-2025
Historic Operating Leases for Travere Therapeutics (TVTX) over the last 4 years, with Sep 2025 value amounting to $18.4 million.
- Travere Therapeutics' Operating Leases fell 23.03% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year decrease of 23.03%. This contributed to the annual value of $17.2 million for FY2024, which is 23.97% down from last year.
- Per Travere Therapeutics' latest filing, its Operating Leases stood at $18.4 million for Q3 2025, which was down 6.80% from $19.7 million recorded in Q2 2025.
- Travere Therapeutics' 5-year Operating Leases high stood at $34.5 million for Q1 2022, and its period low was $17.2 million during Q4 2024.
- In the last 3 years, Travere Therapeutics' Operating Leases had a median value of $23.9 million in 2024 and averaged $24.0 million.
- As far as peak fluctuations go, Travere Therapeutics' Operating Leases grew by 11.16% in 2021, and later declined by 23.97% in 2024.
- Quarterly analysis of 5 years shows Travere Therapeutics' Operating Leases stood at $31.5 million in 2021, then declined by 12.66% to $27.5 million in 2022, then decreased by 17.80% to $22.6 million in 2023, then decreased by 23.97% to $17.2 million in 2024, then dropped by 23.03% to $18.4 million in 2025.
- Its Operating Leases stands at $18.4 million for Q3 2025, versus $19.7 million for Q2 2025 and $21.0 million for Q1 2025.